Company Profile

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized polymerase chain reaction (PCR) master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi'in, Israel. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany.

Employees

704

Sector

Medical Equipment, Supplies & Distribution

More about the company

07-14	Meridian Bioscience, Inc. Receives Health Canada License For Alethia CMV Assay	CI
06-10	Meridian Bioscience, Inc. and 4Bases Announce Collaboration to Enable Rapid Globally Scalable Next-Generation Sequencing Workflows	CI
02-18	Meridian Bioscience, Inc. Announces the Launch of Its Lyophilized NGS Enzymatic DNA Fragmentation Kit	CI
01-28	U.S. Department of Health and Human Services Issues Warning Letter to Meridian Bioscience, Inc	CI
01-28	U.S. Department of Health and Human Services Issues Warning Letter to Meridian Bioscience, Inc	CI
01-28	U.S. Department of Health and Human Services Issues Warning Letter to Meridian Bioscience, Inc	CI
25-10-14	Meridian Bioscience, Inc. Announces Chief Financial Officer Changes, Effective October 14, 2025	CI
25-10-14	Meridian Bioscience, Inc. Announces Executive Changes	CI
25-10-14	Meridian Bioscience, Inc. Promotes Andy Kitzmiller to Chief Executive Officer, Effective October 14, 2025	CI
25-09-16	Meridian Bioscience, Inc. Eliminates Cold Chain with the First Liquid Ambient Temperature Stable qPCR Master Mixes	CI
25-04-23	Meridian Bioscience Introduces New Enzyme Stabilization Services for Molecular Diagnostics	CI
24-07-23	Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in Vitro Diagnostic Manufacturers	CI
24-06-26	Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage	CI

22-07-08	HC Wainwright Downgrades Meridian Bioscience to Neutral From Buy, Adjusts Price Target to $34 From $30	MT
22-07-07	William Blair Downgrades Meridian Bioscience to Market Perform from Outperform	MT
22-02-07	HC Wainwright Adjusts Meridian Bioscience's Price Target to $30 From $28, Keeps Buy Rating	MT
21-08-09	Meridian Bioscience : HC Wainwright Adjusts Meridian Bioscience's Price Target to $27 From $30, Keeps Buy Rating	MT
21-05-10	Meridian Bioscience : HC Wainwright Adjusts Meridian Bioscience PT to $30 From $32, Maintains Buy Rating	MT

23-07-25	Meridian Bioscience Sets a New Sustainability Standard in Diagnostic Assay Development with the Launch of Two New Animal-Free Immunoassay Interference Blockers	AQ
23-02-09	MERIDIAN BIOSCIENCE INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
23-02-01	MERIDIAN BIOSCIENCE INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial S (form 8-K)	AQ
23-01-31	SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience	PR
23-01-13	SD Biosensor Successfully Finishes JP Morgan Healthcare Conference 2023	AQ

17-04-24	Meridian Bioscience : Neues Testverfahren kann wichtiges Werkzeug im globalen Kampf gegen Malaria warden
17-04-24	Meridian Bioscience : La nouvelle procédure de test semble prometteuse comme outil essentiel dans l'effort mondial qui vise à éliminer le paludisme
17-04-18	Meridian Bioscience : Vortrag über einen revolutionären Durchbruch für die Erkennung von Malariaparasiten auf dem ECCMID
17-03-28	Meridian Bioscience : Bioline lance de nouveaux kits de quantification d'ADN JetSeq
17-03-28	Meridian Bioscience : Bioline bringt neue JetSeq-DNA-Quantifizierungs-Kits auf den Markt

Manager	Title	Age	Since
Andrew Kitzmiller CEO	Chief Executive Officer	47	2025-10-13
Julie Smith DFI	Director of Finance/CFO	58	2025-10-13
Don Oliver CTO	Chief Tech/Sci/R&D Officer	-	-

Meridian Bioscience, Inc. Stock

Stocks

VIVO

US5895841014

Medical Equipment, Supplies & Distribution

Latest news : Meridian Bioscience, Inc.

Analysts' recommendations: Meridian Bioscience, Inc.

Press Releases: Meridian Bioscience, Inc.

News in other languages: Meridian Bioscience, Inc.

Managers and Directors: Meridian Bioscience, Inc.

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/31/23	Felicia Williams	Issuer sale	Director	59,671	0.1361%
1/31/23	John McIlwraith	Issuer sale	Chairman	98,121	0.2239%
1/31/23	Julie Smith	Free	Chief Financial Officer	62,956	0.1436%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MERIDIAN BIOSCIENCE, INC.	-.--%	+0.32%	-	-	1.49B
ABBOTT LABORATORIES	-0.02%	+3.19%	-15.56%	+6.43%	193B
MEDTRONIC PLC	+0.76%	+4.72%	-1.88%	+11.89%	117B
CENCORA, INC.	+1.23%	-2.07%	+7.17%	+70.56%	59.89B
HOYA CORPORATION	-0.92%	+0.57%	+34.56%	+70.98%	56.01B
BECTON, DICKINSON AND COMPANY	+0.79%	+3.70%	-6.40%	-33.73%	49.96B
DEXCOM, INC.	-1.89%	+5.90%	+10.87%	-19.26%	33.87B
MEDLINE INC.	+0.45%	+1.45%	-	-	31.36B
TERUMO CORPORATION	-1.96%	+1.73%	-6.04%	+27.56%	24.77B
WEST PHARMACEUTICAL SERVICES, INC.	+0.94%	-1.31%	+41.93%	-12.09%	24.59B
Average	-0.04%	+3.57%	+8.08%	+15.29%	65.53B
Weighted average by Cap.	+0.14%	+3.34%	+0.14%	+15.90%